No Data
Larimar Stock Rallies 24% on FDA Removal of Partial Clinical Hold
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Express News | Design Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate
Express News | Design Therapeutics Inc - Qtrly Shr Loss $0.20